Bertis, a South Korean proteomics-based precision medicine technology company, has established a US-based wholly-owned entity to expand its global presence.
The subsidiary, called Bertis Bioscience, aims to establish a San Diego-based CLIA-certified lab facility in early Q4, 2022. It will offer proteomics-based screening and diagnostic tests, as well as an analysis platform to integrate multi-omics data.
Proteomics, the study of proteins in the human body, has emerged as a promising field in medicine, particularly for its potential to identify subtypes of cancers and match patients with the most appropriate treatment strategy.
In South Korea, Bertis created MASTOCHECK, the world’s first proteomics-based breast cancer blood test solution. The test received marketing approval as an in vitro diagnostic medical device from the Ministry of Food and Drug Safety in January 2019.
In September, Bertis’ research team presented protein biomarkers for early diagnosis of high-grade serous ovarian cancer (HGSOC) with 95% accuracy. The results of this study were published in the Journal of Proteome Research by the American Chemical Society.
